These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21353887)

  • 1. Activin A in nonalcoholic fatty liver disease.
    Yndestad A; Haukeland JW; Dahl TB; Halvorsen B; Aukrust P
    Vitam Horm; 2011; 85():323-42. PubMed ID: 21353887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of disease progression in nonalcoholic fatty liver disease.
    Jou J; Choi SS; Diehl AM
    Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty liver: role of inflammation and fatty acid nutrition.
    Byrne CD
    Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.
    Carter-Kent C; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Apr; 103(4):1036-42. PubMed ID: 18177455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease (NAFLD): a comprehensive review.
    Salt WB
    J Insur Med; 2004; 36(1):27-41. PubMed ID: 15104027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.
    Wanless IR; Shiota K
    Semin Liver Dis; 2004 Feb; 24(1):99-106. PubMed ID: 15085490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities.
    Gambino R; Musso G; Cassader M
    Antioxid Redox Signal; 2011 Sep; 15(5):1325-65. PubMed ID: 20969475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease.
    Aigner E; Strasser M; Haufe H; Sonnweber T; Hohla F; Stadlmayr A; Solioz M; Tilg H; Patsch W; Weiss G; Stickel F; Datz C
    Am J Gastroenterol; 2010 Sep; 105(9):1978-85. PubMed ID: 20407430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation in nonalcoholic steatohepatitis.
    Harmon RC; Tiniakos DG; Argo CK
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):189-200. PubMed ID: 21476914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease.
    Yu AS; Keeffe EB
    Rev Gastroenterol Disord; 2002; 2(1):11-9. PubMed ID: 12122975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activin axis in liver biology and disease.
    Rodgarkia-Dara C; Vejda S; Erlach N; Losert A; Bursch W; Berger W; Schulte-Hermann R; Grusch M
    Mutat Res; 2006; 613(2-3):123-37. PubMed ID: 16997617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of nonalcoholic steatohepatitis (NASH).
    Ma X; Li Z
    Chin J Dig Dis; 2006; 7(1):7-11. PubMed ID: 16412031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.
    Tiniakos DG
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):643-50. PubMed ID: 19478676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.
    Wieckowska A; McCullough AJ; Feldstein AE
    Hepatology; 2007 Aug; 46(2):582-9. PubMed ID: 17661414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.